PMC:7408073 / 67841-68051 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T419","span":{"begin":65,"end":72},"obj":"Body_part"}],"attributes":[{"id":"A419","pred":"fma_id","subj":"T419","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"n both ACE2 catalytic activity and ACE2 binding domain for spike protein of SARS-CoV [127]. Unfortunately, NAAE has never been used in vivo. Indeed, NAAE is a weak ACE2 inhibitor, it is in fact more than a thou"}

{"project":"LitCovid-PubTator","denotations":[{"id":"2402","span":{"begin":7,"end":11},"obj":"Gene"},{"id":"2403","span":{"begin":35,"end":39},"obj":"Gene"},{"id":"2404","span":{"begin":164,"end":168},"obj":"Gene"},{"id":"2410","span":{"begin":59,"end":64},"obj":"Gene"},{"id":"2412","span":{"begin":76,"end":84},"obj":"Species"},{"id":"2419","span":{"begin":107,"end":111},"obj":"Chemical"},{"id":"2420","span":{"begin":149,"end":153},"obj":"Chemical"}],"attributes":[{"id":"A2402","pred":"tao:has_database_id","subj":"2402","obj":"Gene:59272"},{"id":"A2403","pred":"tao:has_database_id","subj":"2403","obj":"Gene:59272"},{"id":"A2404","pred":"tao:has_database_id","subj":"2404","obj":"Gene:59272"},{"id":"A2410","pred":"tao:has_database_id","subj":"2410","obj":"Gene:43740568"},{"id":"A2412","pred":"tao:has_database_id","subj":"2412","obj":"Tax:694009"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"n both ACE2 catalytic activity and ACE2 binding domain for spike protein of SARS-CoV [127]. Unfortunately, NAAE has never been used in vivo. Indeed, NAAE is a weak ACE2 inhibitor, it is in fact more than a thou"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T332","span":{"begin":76,"end":84},"obj":"Disease"},{"id":"T333","span":{"begin":76,"end":80},"obj":"Disease"}],"attributes":[{"id":"A332","pred":"mondo_id","subj":"T332","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A333","pred":"mondo_id","subj":"T333","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"n both ACE2 catalytic activity and ACE2 binding domain for spike protein of SARS-CoV [127]. Unfortunately, NAAE has never been used in vivo. Indeed, NAAE is a weak ACE2 inhibitor, it is in fact more than a thou"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T846","span":{"begin":22,"end":30},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T847","span":{"begin":112,"end":115},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T848","span":{"begin":157,"end":158},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T849","span":{"begin":204,"end":205},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"n both ACE2 catalytic activity and ACE2 binding domain for spike protein of SARS-CoV [127]. Unfortunately, NAAE has never been used in vivo. Indeed, NAAE is a weak ACE2 inhibitor, it is in fact more than a thou"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T50950","span":{"begin":65,"end":72},"obj":"Chemical"},{"id":"T79228","span":{"begin":164,"end":178},"obj":"Chemical"},{"id":"T7622","span":{"begin":169,"end":178},"obj":"Chemical"}],"attributes":[{"id":"A8296","pred":"chebi_id","subj":"T50950","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A75532","pred":"chebi_id","subj":"T79228","obj":"http://purl.obolibrary.org/obo/CHEBI_147289"},{"id":"A90646","pred":"chebi_id","subj":"T7622","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"n both ACE2 catalytic activity and ACE2 binding domain for spike protein of SARS-CoV [127]. Unfortunately, NAAE has never been used in vivo. Indeed, NAAE is a weak ACE2 inhibitor, it is in fact more than a thou"}

{"project":"LitCovid-sentences","denotations":[{"id":"T330","span":{"begin":92,"end":140},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"n both ACE2 catalytic activity and ACE2 binding domain for spike protein of SARS-CoV [127]. Unfortunately, NAAE has never been used in vivo. Indeed, NAAE is a weak ACE2 inhibitor, it is in fact more than a thou"}

{"project":"2_test","denotations":[{"id":"32708755-15492138-20678884","span":{"begin":86,"end":89},"obj":"15492138"}],"text":"n both ACE2 catalytic activity and ACE2 binding domain for spike protein of SARS-CoV [127]. Unfortunately, NAAE has never been used in vivo. Indeed, NAAE is a weak ACE2 inhibitor, it is in fact more than a thou"}